Dr. Mark Stein, Principal Investigator of the first-in-man trial will discuss the results of the first-in-human dose escalation study of oral ONC201 in advanced solid tumors at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, Massachusetts and will be published in the online Proceedings.
Session ID: Poster Session C
Session Title: New Molecular Targets
Session Date and Time: Sunday Nov 8, 2015 12:30 PM – 3:30 PM
Location: Exhibit Hall C-D
Permanent Abstract Number: C137